

## Primary Health Properties

### Delivering on the promised merger synergies

#### HOLD

Target price 130p | Published price 134p

PHP's underlying performance was positive through H1, with improving rental growth and a 1-2bps contraction in net initial yields. NAV remained flat at 105.2p, 2% ahead of our forecast, with a +0.8% LFL property valuation gain (+£17.7m) offset by merger costs. EPRA EPS +12% y/y and DPS +4% were broadly in line with our forecasts. Positively, rent reviews have shown further steady improvement with annualised growth of 1.9% rising from 1.7%. Synergies have already delivered a £4m p.a. reduction in the enlarged group's operating cost base, further enhancing earnings growth. We expect PHP's portfolio to continue to benefit from long-term structural growth, driven by a growing and ageing UK population coupled with efforts to improve the efficiency and cost effectiveness of the NHS by expanding the scope of services provided by GPs. The shares trade on a CY19E P/NAV of 1.29x vs the sector at 0.89x and offers a dividend yield of 4.1%.

#### Good start to FY19: NAV 2% ahead of our forecasts

H1 EPRA NAV remained flat on FY18 at 105.2p, 2% ahead of our 103.1p forecast, helped by rental growth and 1-2bps contraction in net initial yields on the portfolio, offsetting a 1.4p impact from the MedicX merger.

EPRA EPS +12% to 2.8p was broadly in line with our 2.9p expectation and the DPS +3.7% to 2.8p was in line with our expectation of 2.8p.

#### Improving rental growth

Positively, annualised rental growth has shown further signs of improvement +1.9% vs. +1.7% in FY18 and narrowing the gap to peer Assura (2.2% as at March 19). Comparable new build evidence, used to price open market reviews, is now beginning to be reflected in lease renewals with management expecting this to result in further rental growth in the future.

The portfolio remains well let at 99.5%, with a long weighted average unexpired lease length of 13.0yrs. The EPRA cost ratio decreased further to 12.2% (vs 14.3% FY18 and 14.2% in H1 last year) as the portfolio benefits from a lower management fee on the enlarged portfolio. The merger with MedicX crystallised a number of operating and finance cost saving synergies and PHP has already delivered a £4.0m p.a. reduction in the enlarged Group's operating costs.

#### 0.8% valuation gain

A +0.8% LFL increase in the property portfolio was ahead of our expectation. PHP saw a 1-2bp contraction in net initial yields in the period but the combination of the MedicX and PHP's portfolios resulted in the blended net initial and true equivalent yields remaining unchanged at 4.85% (vs FY18 4.85%) and 4.99% (vs FY 18 4.99%) respectively. Rental growth environment accounted for the majority of the surplus whilst yield compression accounted for the balance.

## Higher LTV but lower cost of debt

LTV has increased to 47.9% (vs. 44.8% in FY18) following the acquisition of MedicX which operated with a higher LTV. Interest cover at 2.7x remains comfortably above the covenant 1.3x.

PHP issued a £150m convertible bond within the period, replacing the group's £75m retail bond with a lower cost financing option. The bond carries a coupon of 2.875% (vs. the retail bond's 5.375%) and reduces the average weighted cost of debt to 3.75% (vs 3.86% in H1 18). This will, nevertheless, have a dilutive impact on fully diluted EPS.

## A summary of the MedicX acquisition; the purchase of a high quality portfolio

PHP's merger with MedicX completed on 14<sup>th</sup> March 2019. As a result of the transaction, existing PHP shareholders held 69.4% of the enlarged company, with MedicX shareholders holding the balance. PHP and MedicX's portfolio's are highly complementary, offering opportunities from scale benefits and a reduction in the EPRA cost ratio. £4m of savings p.a. are expected from the end of the first full year (0.4p per share in the enlarged company). MedicX's portfolio of properties included 166 in the UK and 5 in Ireland at the time of the merger. Similar to PHP, MedicX had a focus on larger lot sizes, in order to align its portfolio with the rising volumes and broadening scope of services increasingly provided by GPs. The average size per asset of the enlarged PHP group is c.1,300sqm, which compares to c.950sqm at Assura. Larger fit-for-purpose buildings allow greater patient, organisational and cost benefits to the healthcare system, reducing strain on A&E and the wider NHS. We continue to believe this strategy will drive superior value in the long term.

## Taking share in a low-risk, growth market

We expect PHP's portfolio to benefit from long-term structural growth, driven by a growing and ageing UK population coupled with efforts to improve the efficiency and cost effectiveness of the NHS by expanding the scope of services provided by GPs. The majority of the existing primary care estate is considered unfit for purpose to meet this growing demand. Leases are long-dated and contain upward only rent review provisions. The merger with MedicX accelerates the benefits of scale increasing operational efficiency and with the potential to reduce the cost of capital. However, we believe this is fairly reflected in the group's current premium to NAV and premium vs the sector. The shares currently trade on a CY19E P/NAV of 1.29x, with a P/E of 23.1x and a dividend yield of 4.1%.

**Figure 1: Summary financials & valuation (not updated for H1 results)**

<b>Valuation Summary (CY)</b>	<b>2018A</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>
P/NAV (x)	1.28	1.29	1.27	1.26
P/E (x)	25.9	23.1	22.0	20.5
Div Yield (%)	4.0%	4.1%	4.3%	4.5%
EV/Sales (x)	20.5	22.2	20.7	19.9
EV/EBITDA (x)	24.5	25.1	23.3	22.4
EV/EBIT (x)	24.5	25.1	23.3	22.4
FCF Yield (%)	3.6%	2.5%	4.5%	4.8%
<b>Financials (FY - Dec y/e)</b>	<b>2018A</b>	<b>2019E</b>	<b>2020E</b>	<b>2021E</b>
Gross rental income (£m)	79.6	117.8	135.6	145.3
Net rental income (£m)	76.4	114.6	131.8	141.1
Gross to net (%)	96.0%	97.3%	97.2%	97.2%
Adj. EBITDA (£m)	66.5	104.0	120.3	129.4
EBITDA margin (%)	83.5%	88.2%	88.8%	89.0%
Adj. EBIT (£m)	66.5	104.0	120.3	129.4
EBIT margin (%)	83.5%	88.2%	88.8%	89.0%

Adj. net Interest (£m)	-29.7	-42.4	-51.1	-54.6
Adj. PBT (£m)	36.8	61.6	69.3	74.8
<b>Adj. EPRA EPS - diluted (p)</b>	<b>5.2</b>	<b>5.8</b>	<b>6.1</b>	<b>6.6</b>
DPS (p)	5.4	5.6	5.8	6.1
Cover (x)	1.0	1.0	1.1	1.1
<b>Diluted EPRA NAV (p)</b>	<b>105.1</b>	<b>104.3</b>	<b>106.2</b>	<b>106.3</b>
Net cash/(debt) (£m)	-676.6	-1,188.1	-1,276.6	-1,362.6
LTV (%)	45%	49%	51%	52%

Source: Liberum

[Please click here if you would like a meeting](#)

## Research



**James Ashley**

+44 (0)20 3100 2167

[james.ashley@liberum.com](mailto:james.ashley@liberum.com)

## Specialist Sales



**John Mozley**

+44 (0)20 3100 2115

[John.Mozley@liberum.com](mailto:John.Mozley@liberum.com)

If you were forwarded this by a colleague and would like to receive the sector research directly, please click [here >>](#)

If you would like to notify us of a change to your current subscription to Liberum research please click [here >>](#)

This is a marketing communication and is not independent research prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to a prohibition on dealing ahead of the dissemination of investment research.

This communication is issued by Liberum Capital Limited (LCL). Liberum Capital Limited is authorised and regulated by the Financial Conduct Authority (FCA). This email and any attachments to it are confidential and are intended for the named addressee only and may not be re-distributed, retransmitted or disclosed, in whole or in part, or in any manner, without the express written consent of LCL. If you are not the intended recipient of this email please delete it immediately and do not take any action based upon it. This communication is intended for use only by a person or entity that qualifies as a "Professional Client" or an "Eligible Counterparty" within the meaning of the rules of the FCA. Consequently, this communication is intended for use only by persons having professional experience in matters relating to investments. This communication is not intended for use by any other person. Any other person who receives this communication should not act on the contents of this communication.

Internet communications are not secure or error free and although emails are routinely screened for viruses, LCL does not accept responsibility for any computer virus which might be transferred by way of this email. Replies to this email may be monitored.

This communication is for information purposes only and should not be regarded as an offer or solicitation to buy or sell any security. Expressions of opinions are those of the author and the research department of LCL only and are subject to change without notice. The information, data, opinions, estimates and projections contained herein have been obtained from sources which we believe to be reliable. Furthermore, all charts and graphs are from publicly available sources or proprietary data. No representation or warranty either expressed or implied, is made nor responsibility of any kind is accepted by LCL, its officers or employees either as to the accuracy or completeness of any information stated in this document and LCL shall not be liable for any direct or indirect damages, including lost profits, arising in any way from the information contained in this communication. While LCL endeavours to update its research reports from time to time it is under no obligation to do so.

LCL and/or its officers and employees may have or take positions in securities of companies mentioned in this communication (or in any related investment) and may from time to time dispose of any such positions. LCL may act as a market maker in the securities of companies discussed in this communication (or in any related investments), may sell them or buy them from customers on a principal basis, and may also perform underwriting services for or relating to those companies.

LCL may provide or may have provided corporate services to the issuers of securities mentioned in this communication and recipients of this document should not therefore rely on this report as being an impartial document. Accordingly, information may be known to LCL or persons connected with it which is not reflected in this material.

For more information on models, please contact the Analyst.

LCL has a conflicts management policy relating to its investment research activities, which is available upon request. Please contact the LCL Compliance Officer for further details.

For US Investors: Analyst Certification: The analyst(s) who prepared this report hereby certifies that all of the views expressed in this report accurately reflect his / her personal views about the subject securities or issuers. No part of his/her compensation was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this report.

Please refer to [www.liberum.com/legal](http://www.liberum.com/legal) for detailed disclosures

The stated price of any securities mentioned herein is as at the end of the business day immediately prior to the publication date on this document unless otherwise stated and is not a representation that any transaction can be effected at this price. No personal recommendation is being made to you; the securities referred to may not be suitable for you and this material should not be relied upon in substitution for the exercise of independent judgement.

^Completed when first distributed.

Registered in England & Wales No. 5912554 with registered office address Ropemaker Place, Level 12, 25 Ropemaker Street, London EC2Y 9LY, Tel +44 (0)20 3100 2000 Fax +44 (0)20 3100 2299.